Hemostatic agents of broad applicability produced by selective tuning of factor Xa zymogenicity-Reference-Cited by-同舟云学术

Hemostatic agents of broad applicability produced by selective tuning of factor Xa zymogenicity

Published:2015-07-02 Issue:1 Volume:126 Page:94-102
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Ivanciu Lacramioara¹,Camire Rodney M.¹

Affiliation:

1. The Children’s Hospital of Philadelphia, The Center for Cell and Molecular Therapeutics, and Division of Hematology, Department of Pediatrics, The University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA

Abstract

Key Points Modulation of FX(a) zymogenicity yields proteins with a broad range of half-lives and biologic function yet potent in vivo efficacy. Zymogen-like variants are attractive molecules for alleviating bleeding in different clinical scenarios such as hemophilia.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/126/1/94/1345722/94.pdf

Reference35 articles.

1. Modern haemophilia care.;Berntorp;Lancet,2012

2. Hemophilia: new protein therapeutics.;Pipe;Hematology Am Soc Hematol Educ Program,2010

3. Molecular approaches for improved clotting factors for hemophilia.;Kaufman;Blood,2013

4. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia.;Schaub;Biochem Pharmacol,2011

5. The conformational switch from the factor X zymogen to protease state mediates exosite expression and prothrombinase assembly.;Toso;J Biol Chem,2008

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Activated factor X delivered by adeno-associated virus significantly inhibited bleeding and alleviated hemophilic synovitis in hemophilic mice;Gene Therapy;2024-09-10

2. Activated Factor X delivered by Adeno-Associated virus significantly inhibited bleeding and alleviated hemophilia A/B arthropathy in hemophilia mice;2024-01-05

3. Altered cleavage of human factor VIII at the B-domain and acidic region 3 interface enhances expression after gene therapy in hemophilia A mice;Journal of Thrombosis and Haemostasis;2023-08

4. Preclinical studies of a factor X activator and a phase 1 trial for hemophilia patients with inhibitors;Journal of Thrombosis and Haemostasis;2023-06

5. Factor IXa variants resistant to plasma inhibitors enhance clot formation in vivo;Blood;2023-04-20